Stablepharma
PrivateLast Round
Grant
Feb 19, 2025
Est. Valuation
$50.25M
Total Funding Raised
$12.31M
Company Overview
Stablepharma is a biotechnology company that develops a technology platform to transform approved vaccines, therapeutics, and diagnostics into thermostable products, ensuring safe and efficient delivery while minimizing waste and carbon emissions.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Pharma Supply Chain
Business Model
B2B
Customer Profile
Services & Consulting, Revenue Share
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Stablepharma Comparables
Compare Stablepharma with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| VitriVax, Inc. | 87% | |
| Elarex Inc. | 84% | |
| Inaedis Inc. | 84% |
Stablepharma Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Feb 19, 2025 | ||||
| Crowdfunding | Jun 14, 2024 | ||||
| VC Round | Oct 23, 2023 | ||||
| Grant | Sep 12, 2023 | ||||
| Series A | Dec 23, 2022 | ||||
Crowdfunding | Aug 5, 2021 |
Key People
Founding team and executive leadership
Stablepharma Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Crowdcube Investors | Crowdfunding, VC Round, Series A, Seed |
| European Innovation Council Fund | Grant |
| Ascension Ventures | Series A |
| Innovate UK | Grant |
| Oval Investments Limited | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 13, 2026
SPVX02 targets tetanus and diphtheria, developed with UKHSA support.
- Jan 15, 2026
Developing fridge-free sterile injectable medicines with AFT Pharmaceuticals.
Recent news
Latest coverage and updates
- is_developingOct 19, 2026
Stablepharma begins the first human trial of a tetanus-diphtheria vaccine designed to remain stable without refrigeration in the United Kingdom in Apr '25.
- is_developingOct 15, 2026
Stablepharma prepares SPVX02, a thermostable version of an existing tetanus-diphtheria vaccine, for a pivotal Phase 2b clinical trial after a successful Phase 1 trial, with room-temperature storage potentially making transport easier and cheaper in areas without reliable electricity and infrastructure, in United Kingdom on Sep 18th '26.
- recognized_asOct 15, 2026
Stablepharma's lead vaccine candidate, SPVX02, is named one of TIME's Best Inventions of 2026 in the Medical & Healthcare category in United Kingdom on Oct 15th '26'.
- is_developingAug 9, 2026
Stablepharma will develop SPVX02 on Jul 1st '27.
Stablepharma Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Stablepharma's valuation, stock price, and market status.
Is Stablepharma a public or private company?
Stablepharma is a private company.
What is the current stock price of Stablepharma?
Stablepharma is a private company, so its shares have no public market price. Caplight tracks Stablepharma's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Stablepharma worth (valuation)?
Stablepharma's valuation is estimated at $50.3M based on funding round data.
Can I buy Stablepharma stock?
Stablepharma shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Stablepharma's last funding round?
Stablepharma's most recent funding round was Grant on February 19, 2025.
Who are the main investors in Stablepharma?
Key investors in Stablepharma include European Innovation Council Fund, Oval Investments Limited.
Will Stablepharma IPO soon?
No public IPO plans have been announced for Stablepharma.
How can I track Stablepharma secondary market activity?
Caplight tracks bids, offers, and trades in Stablepharma's shares on secondary markets.